These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 27564409)

  • 1. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
    Saag KG; Fitz-Patrick D; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; Becker MA
    Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Kopicko J; Bhakta N; Adler S; Fung M; Storgard C; Baumgartner S; Perez-Ruiz F
    Arthritis Rheumatol; 2017 Sep; 69(9):1903-1913. PubMed ID: 28597604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Fung M; Baumgartner S; Perez-Ruiz F
    Arthritis Res Ther; 2019 Jan; 21(1):8. PubMed ID: 30616614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
    Perez-Ruiz F; Sundy JS; Miner JN; Cravets M; Storgard C;
    Ann Rheum Dis; 2016 Jun; 75(6):1074-80. PubMed ID: 26742777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
    Tausche AK; Alten R; Dalbeth N; Kopicko J; Fung M; Adler S; Bhakta N; Storgard C; Baumgartner S; Saag K
    Rheumatology (Oxford); 2017 Dec; 56(12):2170-2178. PubMed ID: 29029210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
    Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
    Jones G; Panova E; Day R
    Drug Des Devel Ther; 2017; 11():3077-3081. PubMed ID: 29123379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
    Shen Z; Tieu K; Wilson D; Bucci G; Gillen M; Lee C; Kerr B
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lesinurad: A Novel Agent for Management of Chronic Gout.
    Haber SL; Fente G; Fenton SN; Walker EP; Weaver BM; Cano AJ; Vu K
    Ann Pharmacother; 2018 Jul; 52(7):690-696. PubMed ID: 29482353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
    Terkeltaub R; Saag KG; Goldfarb DS; Baumgartner S; Schechter BM; Valiyil R; Jalal D; Pillinger M; White WB
    Rheumatology (Oxford); 2019 Jan; 58(1):61-69. PubMed ID: 30124941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.
    Poiley J; Steinberg AS; Choi YJ; Davis CS; Martin RL; McWherter CA; Boudes PF;
    Arthritis Rheumatol; 2016 Aug; 68(8):2027-34. PubMed ID: 26989892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
    Saag KG; Becker MA; Whelton A; Hunt B; Castillo M; Kisfalvi K; Gunawardhana L
    Arthritis Rheumatol; 2019 Jan; 71(1):143-153. PubMed ID: 30073793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.
    Pérez-Ruiz F; Jansen T; Tausche AK; Juárez-Campo M; Gurunath RK; Richette P
    Drugs Context; 2019; 8():212581. PubMed ID: 31191704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.